Cargando…

Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition

PURPOSE OF REVIEW: The moderate glucose-lowering effect of sodium glucose co-transporter 2 (SGLT2) inhibitors is unlikely to explain SGLT2 inhibitor-mediated beneficial outcomes, and unravelling the underlying mechanisms is a high priority in the research community. Given the dominant pathophysiolog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herat, Lakshini Y., Matthews, Jennifer, Azzam, Omar, Schlaich, Markus P., Matthews, Vance B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Hypertension and Metabolic Syndrome (J Sperati, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942945/ https://www.ncbi.nlm.nih.gov/pubmed/35235172 http://dx.doi.org/10.1007/s11906-022-01170-z

Ejemplares similares

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
por: Matthews, Jennifer, et al.
Publicado: (2022)

Hypertension and Metabolic Syndrome in Persons with HIV
por: Masenga, Sepiso K., et al.
Publicado: (2020)

11β-Hydroxysteroid Dehydrogenases and Hypertension in the Metabolic Syndrome
por: Bailey, Matthew A.
Publicado: (2017)

Migrating Populations and Health: Risk Factors for Cardiovascular Disease and Metabolic Syndrome
por: Rosenthal, Talma, et al.
Publicado: (2022)

Time-Restricted Eating in Metabolic Syndrome–Focus on Blood Pressure Outcomes
por: Duan, Daisy, et al.
Publicado: (2022)

Role of MicroRNA in Endothelial Dysfunction and Hypertension
por: Nemecz, Miruna, et al.
Publicado: (2016)

Implications of ADAM17 activation for hyperglycaemia, obesity and type 2 diabetes
por: Matthews, Jennifer, et al.
Publicado: (2021)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
por: Matthews, Jennifer, et al.
Publicado: (2023)

Management of Hypertension in the Obese Pregnant Patient
por: Coroyannakis, Christina, et al.
Publicado: (2019)

The Effect of SGLT2 Inhibition on Diabetic Kidney Disease in a Model of Diabetic Retinopathy
por: Matthews, Jennifer Rose, et al.
Publicado: (2022)

SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes
por: Herat, Lakshini Yasaswi, et al.
Publicado: (2023)

SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for Beiging
por: Matthews, Jennifer R., et al.
Publicado: (2020)

The Sympathetic Nervous System Regulates Sodium Glucose Co-Transporter 1 Expression in the Kidney
por: Matthews, Jennifer, et al.
Publicado: (2023)

The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice
por: Herat, Lakshini, et al.
Publicado: (2017)

Sympathetic stimulation with norepinephrine may come at a cost
por: Herat, Lakshini Y., et al.
Publicado: (2019)

Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy
por: Herat, Lakshini Y., et al.
Publicado: (2018)

Current Knowledge of IL-6 Cytokine Family Members in Acute and Chronic Kidney Disease
por: Magno, Aaron L., et al.
Publicado: (2019)

SGLT2 Inhibitor–Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection
por: Herat, Lakshini Y., et al.
Publicado: (2020)

TNFSF14-Derived Molecules as a Novel Treatment for Obesity and Type 2 Diabetes
por: Agostino, Mark, et al.
Publicado: (2021)

Weight change over five-year periods and number of components of the metabolic syndrome in a Dutch cohort
por: Bot, M., et al.
Publicado: (2010)

Obesity preventive function of novel edible mushroom, Basidiomycetes-X (Echigoshirayukidake): Manipulations of insulin resistance and lipid metabolism
por: Khatun, Mst Afifa, et al.
Publicado: (2020)

The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α
por: Magno, Aaron L., et al.
Publicado: (2020)

Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice
por: Herat, Lakshini Y, et al.
Publicado: (2020)

Use of machine-learning algorithms to determine features of systolic blood pressure variability that predict poor outcomes in hypertensive patients
por: Lacson, Ronilda C, et al.
Publicado: (2018)

Relationship Between Blood Pressure Values, Depressive Symptoms, and Cardiovascular Outcomes in Patients With Cardiometabolic Disease
por: Jani, Bhautesh Dinesh, et al.
Publicado: (2016)

Supine blood pressure—A clinically relevant determinant of vascular target organ damage in hypertensive patients
por: Nolde, Janis M., et al.
Publicado: (2020)

Combined renal and common hepatic artery denervation as a novel approach to reduce cardiometabolic risk: technical approach, feasibility and safety in a pre-clinical model
por: Kiuchi, Márcio Galindo, et al.
Publicado: (2021)

Central sympatholytics prolong survival in experimental sepsis
por: Hofer, Stefan, et al.
Publicado: (2009)

The Schlager mouse as a model of altered retinal phenotype
por: Herat, Lakshini Y., et al.
Publicado: (2019)

Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—A Condition Associated with Heightened Sympathetic Activation
por: Carnagarin, Revathy, et al.
Publicado: (2021)

Inositols and metabolic disorders: From farm to bedside
por: Caputo, M., et al.
Publicado: (2020)

Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin’s Effects in the Adrenal Gland
por: Lymperopoulos, Anastasios, et al.
Publicado: (2021)

The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg
por: Schrader, J, et al.
Publicado: (2009)

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms
por: Avogaro, Angelo, et al.
Publicado: (2011)

Endothelial Factors and Diabetic Nephropathy
por: Karalliedde, Janaka, et al.
Publicado: (2011)

Benefits of Tight Blood Pressure Control in Diabetic Patients With Hypertension: Importance of early and sustained implementation of effective treatment strategies
por: Parati, Gianfranco, et al.
Publicado: (2011)

Antihypertensive Treatment and Blood Pressure in Diabetic and Nondiabetic Patients: The lower, the better?
por: Mancia, Giuseppe, et al.
Publicado: (2011)

Blood Pressure: The Lower, the Better: The con side
por: Grossman, Ehud
Publicado: (2011)

Diuretic Treatment of Hypertension
por: Grossman, Ehud, et al.
Publicado: (2011)

RAS Blockade for Every Diabetic Patient: Pro and Con
por: Ruilope, Luis M., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_hn7hrmgup6jib7m23k0alvja41